Anticoagulants Market Size, Share, and Trends 2024 to 2034

Anticoagulants Market Size and Companies

The global anticoagulants market size was estimated at USD 31.04 billion in 2023 and it is projected to surpass around USD 75.53 billion by 2033, growing at a registered CAGR of 9.3% during the forecast period 2024 to 2033. Anticoagulants are commonly known as blood thinners which are basically chemical substances that prevent coagulation of blood. The medicines that help in preventing the blood clots it is administered for people which are at a high risk of getting there close to reduce the chances of developing some other conditions that could be harmful and false heart attacks or strokes. In order to stop bleeding from the wounds the blood clot is a seal which is created by the blood. Blood clots could potentially block a blood vessel and disrupt the blood flow around the body.

Anticoagulants Market Key Takeaways

• North America region accounted for 58.14% market share in 2023.
• By indicated disease, the pulmonary embolism segment has contributed 75% market share in 2023.
• By drug category, the factor Xa inhibitor segment accounted for 56% market share in 2023.
• By distribution channel, the hospital pharmacy segment made up 50% market share in 2023.

U.S. Anticoagulants Market Size and Growth 2024 to 2033

The U.S. anticoagulants market size was estimated at USD 12.66 billion in 2023 and is predicted to be worth around USD 32.13 billion by 2033, at a CAGR of 9.8% from 2024 to 2033.

North American region has generated the largest revenue in the recent years and it is anticipated to dominate the global market in the forecast. North America anticoagulants market size was valued at USD 18.05 billion in 2023. Due to the increasing prevalence of cardiovascular diseases and the treatment which is required coupled together is driving the market in this region. Due to the new product launches in the anticoagulants industry the market is expected to grow. As an increase cases of obesity and diabetes in general public across North American region there shall be an increase in the demand for anticoagulants.

Asia Pacific region is also expected to witness good growth in terms of market value. That's a greater awareness with respect to cardiovascular diseases in this region and increasing disposable income with the people is leading to a growth in the market. Due to the prevailing cardiovascular diseases there's a lot option of advanced anticoagulants in order to improve the condition of the patients. As cardiovascular diseases are the leading cause of mortality in this region this factor happens to drive the market for blood thinners across the Asia Pacific region. Since the cardiovascular diseases cause more than half of all deaths in the European region the market is expected to grow. UK France and Germany contribute to the growth of the European market. During the forecast period there shall be a steady growth in the Middle East and African countries. The anticoagulant drugs will undergo a good growth in the Latin American market. China is expected to witness growth at a CAGR exceeding 8.2% until 2033.

Anticoagulants Markets in the Europe are expected to grow significantly in the years to come, as a result of increasing prevalence of cardiovascular disease, which in turn is increasing the adoption rates of the medications like blood thinning. For instance, according to the European Cardiovascular Disease Statistics, cardiovascular disease registers for more than 45% of all the deaths in Europe. Germany, UK, and France are predicted to contribute to the robust growth of the markets in the Europe.

Markets in the Latin America and the Middle East & Africa (LAMEA) are projected to attain steady growth. This growth is in account of growing propensity of cardiac disorders like heart attacks. An increasing consumption of developed anticoagulant drugs is another factor boosting the growth of this market in the LAMEA region.

Anticoagulants Market Growth Factors 

Due to an increase in the number of critical and serious diseases across the globe is helping in the growth of the market. There's a high prevalence of cardiovascular diseases across the globe which is driven by modern lifestyle changes. These cardiovascular disease of the heart and the blood vessels have life threatening conditions like hypertension, coronary heart disease and hyperlipidemia. It could result in to heart attacks or strokes. Mostly the cardiovascular disorders can be treated with cardiovascular drugs which has a component of anticoagulants. Without the presence of these anticoagulants in the medicines administered to the consumers the formation of blood clots increases. Which may lead to heart attacks and other serious conditions. Cynthia development of anticoagulant products will boost the market growth. There's an increased awareness regarding the cardiovascular health and the negative impact in case the health is neglected. Blood thinning medications play a very important role in the Health Protection by preventing the creation of blood clots. Due to the launch of new type of therapeutics known as the novel oral anticoagulants are contributing to the growth of the market apixaban and rivaroxaban are the novel oral anticoagulants.

Major market players have introduced anticoagulants in order to address the critical treatment needs with respect to the blood clots. There has been major aren't innovations in the anticoagulants market ever since its inception. Currently across the globe there are two major anticoagulants namely Xarelto and Eliquis. This product was introduced by Bristol Myers Squibb company and Pfizer Inc. This product has high sales volume as it was efficient in reducing the superior risks compared to all the other drugs that are offered across the globe.

Growing propensity of cardiac disorders and the growing demand for blood thinners is one of the major factors driving the growth of the global anticoagulants market during the forecast period. Before its introduction in the market, anticoagulants have gone through several research and developments innovations. The rate of success of novel treatments like NOACs in the market from the time of launch is very high. There are two most sold coagulants present in the market, namely Xarelto, and Eliquis. A great existence of generics and other projected launches of coagulants are expected to hamper the growth of this market.

Anticoagulants Market Scope

Indicated Disease Insights

On the basis of the indicated disease, the pulmonary embolism segment accounted market share of 75% in 2023. This is an extremely life threatening condition which may lead to other serious condition which is known as the deep vein thrombosis. Other contributing factors to pulmonary embolism which are obesity cancer and heart disease shall help in the growth of the market. The different campuses segment has grown due to the prevalence of pulmonary embolism and increased conditions of blood disorders obesity and cardiovascular conditions. The heart attack segment is also expected to see a growth during the forecast period due to specially in individuals who have already suffered one heart attack.

Drug Class Insights

With respect to drug class, the market is classified into NOACs, heparin & LMWH, vitamin K antagonist, and others. Among these sub-segments, NOACs is expected to account for the largest revenue share as well as is anticipated to exhibit the fastest growth among all the sub-segments over the forecast timeframe. This growth is attributed towards the increasing adoption of NOACs emerging nations and growing usage of NOACs instead of the warfarin. There are various NOAC drugs present in the market namely betrixaban, edoxaban, rivaroxaban, dabigatran, and apixaban. These drugs come with lot of benefits like quick in action, minimum contact with food and drugs, among others, which in turn are influencing the growth of this market. 

Administration Route Insights

On the basis of the administration route, the oral route is expected to have the largest market share in terms of revenue during the forecast period. Oral anticoagulants are expected to generate the highest market revenue. Oral coolants are one of the most traditional modes or most common modes of administration of an anticoagulant to the patient. Due to the prominent product launches in this segment the market is expected to grow as oral anticoagulants contribute to substantial reduction of the risk.

Distribution Channel Insights

By distribution channel, the hospital pharmacy segment holds the highest market share 50% in 2023. As the usage of anticoagulants is risky and it all often needs prescription after a thorough diagnosis the hospital pharmacy is happen to be the best locations for the sales. As per the current trends of the anticoagulants market the retail pharmacy segment is also expected to hold the second largest share. Retail pharmacies are able to provide efficient facilities in case of refilling prescriptions. Apart from the retail segment the online pharmacy segment is also expected to have the highest during the forecast period as there is an increasing usage of online pharmacy facilities by various nations. Online pharmacies are gaining popularity due to the ease and convenience it provides.

Anticoagulants Market Companies

• Johnson & Johnson
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company
• Bayer AG
• Boehringer Ingelheim GmbH
• Aspen Holdings
• GlaxoSmithKline Plc
• Pfizer Inc.
• Sanofi S.A.
• Portola Pharmaceuticals

Recent Developments

• Xia inhibitor Asundexian, an oral factor of Bayer was permitted fast track status by the Food and Drug Administration of the United Stated in February, 2022. This drug was in second phase of testing which could provide safety benefits over present drugs.
• Anticoagulation treatment was being used by the Stony Brook Study to discover D-Dimer levels lowered fatality in highly diseased patients of the COVID-19, in February, 2021.
• An agreement was signed by Mylan N.V. to acquire Aspen Pharmacare Holdings to get aid in positioning for one of the largest suppliers of injective anticoagulants to customers in the Europe region. The agreement was signed in September, 2020.
• Aspen Pharmacare Holdings received an investment of $756 million from Mylan to bolster its product offerings, in September, 2020.

Segments covered in the report

By Indication of disease

• Pulmonary Embolism (PE)
• Deep Vein Thrombosis (DVT)
• Atrial Fibrillation
• Heart Attacks
• Others

By Administration Route

• Oral
• Injectable

By Drug Class

• NOACs
  • Eliquis
  • Bevyxxa
  • Xarelto
  • Savaysa & lixiana
  • Pradaxa
• Heparin & LMWH
• Vitamin K Antagonist
• Others 

By Distribution Channel 

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacy
• Others

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa